Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Oral F/TAF for HIV Prevention
NCT02904369Phase 1Completed
- Sponsor
- CONRAD
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by CONRAD. Primary endpoints: Plasma concentrations of tenofovir alafenamide, tenofovir, and emtricitabine at Day 17, PBMC concentrations of tenofovir-diphosphate and emtricitabine-triphosphate at Day 17 and 5 more. Started Oct 2016; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02904369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02904369.